Design Therapeutics (DSGN) Projected to Post Quarterly Earnings on Monday

Design Therapeutics (NASDAQ:DSGN) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Design Therapeutics Price Performance

DSGN opened at $10.05 on Friday. The stock has a market capitalization of $572.45 million, a price-to-earnings ratio of -8.45 and a beta of 1.63. The business has a 50-day moving average of $9.96 and a two-hundred day moving average of $8.17. Design Therapeutics has a 12 month low of $2.60 and a 12 month high of $11.14.

Wall Street Analysts Forecast Growth

DSGN has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a report on Wednesday, January 21st. Leerink Partners set a $14.00 price objective on shares of Design Therapeutics and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Oppenheimer started coverage on shares of Design Therapeutics in a report on Wednesday, January 7th. They issued an “outperform” rating and a $18.00 target price on the stock. Craig Hallum assumed coverage on Design Therapeutics in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 target price for the company. Finally, Wall Street Zen raised Design Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Institutional Trading of Design Therapeutics

Several hedge funds have recently bought and sold shares of DSGN. Virtu Financial LLC bought a new position in Design Therapeutics in the 4th quarter worth about $212,000. Invesco Ltd. boosted its position in shares of Design Therapeutics by 1,995.8% during the fourth quarter. Invesco Ltd. now owns 305,757 shares of the company’s stock worth $2,868,000 after buying an additional 291,168 shares during the period. Corient Private Wealth LLC bought a new position in Design Therapeutics in the 4th quarter worth approximately $253,000. XTX Topco Ltd grew its holdings in Design Therapeutics by 197.3% in the 4th quarter. XTX Topco Ltd now owns 35,284 shares of the company’s stock worth $331,000 after buying an additional 23,416 shares in the last quarter. Finally, Millennium Management LLC increased its position in Design Therapeutics by 162.8% in the 4th quarter. Millennium Management LLC now owns 180,866 shares of the company’s stock valued at $1,697,000 after acquiring an additional 112,043 shares during the period. 56.64% of the stock is currently owned by institutional investors.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.